ZIMBABWE – Shares of Biotie Therapies Oyj (NASDAQ:BITI) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus target price of $28.00 for the company and are anticipating that the company will post ($0.79) EPS for the current quarter, according to Zacks. Zacks has also assigned Biotie Therapies Oyj an industry rank of 103 out of 265 based on the ratings given to related companies.
Shares of Biotie Therapies Oyj (NAZDAQ:BITI) traded up 3.70% during midday trading on Monday, hitting $14.30. The company had a trading volume of 36,521 shares. Biotie Therapies Oyj has a 12 month low of $12.75 and a 12 month high of $25.39. The company’s market capitalization is $175.32 million. The company has a 50-day moving average of $15.72 and a 200-day moving average of $17.80.
Biotie Therapies Oyj (NASDAQ:BITI) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($1.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by $0.67. Analysts predict that Biotie Therapies Oyj will post ($2.89) earnings per share for the current year.
BITI has been the subject of several research reports. Zacks lowered Biotie Therapies Oyj from a “hold” rating to a “sell” rating in a research report on Tuesday, September 22nd. RBC Capital reiterated an “outperform” rating and issued a $35.00 price objective on shares of Biotie Therapies Oyj in a report on Monday, September 28th. JMP Securities assumed coverage on Biotie Therapies Oyj in a research note on Monday, July 6th. They set an “outperform” rating and a $32.00 price target on the stock. Roth Capital began coverage on Biotie Therapies Oyj in a research note on Tuesday, July 7th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Stifel Nicolaus began coverage on Biotie Therapies Oyj in a report on Monday, July 6th. They issued a “buy” rating and a $30.00 target price on the stock.
Biotie Therapies Oyj is a Finland-based biopharmaceutical company, which specializes in the field of neurodegenerative and psychiatric disorders. Its product portfolio comprises six drugs: Selincro (NAZDAQ:BITI), an orally administered opioid receptor ligand applied in the alcohol dependence therapy; Tozadenant (SYN115), a is an oral, potent and selective adenosine 2a (A2a) receptor antagonist for the Parkinson’s disease treatment; NRL-1, a intranasal formulation of diazepam for patients with epilepsy; Nepicastat (SYN117), an orally administered, potent and selective inhibitor of dopamine beta hydroxylase (DBH) for the cocaine dependence treatment; BTT-1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 (VAP-1) used in inflammation and fibrosis treatment; and SYN120, an oral, potent and dual antagonist of the 5-HT6 and 5HT2a receptors used in Alzheimer’s disease and other cognitive disorders, such as schizophrenia. It is a parent of Biotie Therapies GmbH, among others.